Bone Biologics filed a patent application with the U.S. Patent and Trademark Office for its NELL-1 protein, according to a June 27 news release.
The patent applies to rhNELL-1 polypeptide and its use for treating bone conditions. The protein is used for spinal fusions.
If approved, the patent will support Bone Biologics’ intellectual property portfolio and plans to advance clinical development.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
